IRIDEX Corp
iridex.comWhat Do They Do?
Sells laser systems, delivery devices and disposable probes for retinal disease and glaucoma treatment to ophthalmologists, hospitals and clinics.
10-K for FY2026, filed Apr 2, 2026IRIDEX Corporation (“IRIDEX”) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough…View ↗
Our products consist of laser consoles, delivery devices and consumable probes.View ↗
Our products are currently sold for use by ophthalmologists specializing in the treatment of eye disease in retinal, glaucoma and pediatric…View ↗
How Do They Make Money?
IRIDEX sells laser consoles, delivery devices and probes, with product sales bringing in money when sold. Service contracts bring in revenue over their coverage periods, repairs as the work is done, royalties as licensees sell products, and exclusive distribution fees over the agreement term.
10-K for FY2026, filed Apr 2, 2026Product Sale Only: The Company’s products consist of laser consoles, delivery devices and consumable instrumentation, including laser…View ↗
The Company recognizes revenue from product sales at a point in time subject to the allocation of transaction price to additional…View ↗
The Company recognizes revenue from service contracts ratably over the service period. Revenue recognition for the sale of a service…View ↗
The Company recognizes revenue from system repairs (outside of warranty) at a point in time. When the customer requests repairs from the…View ↗
Royalty Revenue: The Company has royalty agreements with three customers related to the sale of the Company’s intellectual property. Under…View ↗
Exclusive Distribution Rights: On March 2, 2021, the Company and Topcon Corporation (“Topcon”) entered into a distribution agreement…View ↗
$52.7M
-
10-K for FY2026, filed Apr 2, 2026
$52.7M ↗
Who Are Their Customers?
Its customers include ophthalmologists and medical facilities, including hospitals, surgical centers, clinics and veterinary practices. It sells directly to end users in the United States and Germany and through independent distributors in other countries.
10-K for FY2026, filed Apr 2, 2026
10-K for FY2026, filed Apr 2, 2026
The Company markets its products to distributors and end-users throughout the world. Sales to international distributors are generally made…View ↗
Do Revenues Turn Into Profits?
No. It lost $4.4M in FY2026.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 18, 2026
−$1.3MView ↗
- ▲ +27% (Loss)
- vs −$994K in Q2 FY2025
-
Sep 2, 2026
IRIDEX received a Nasdaq minimum-bid-price deficiency notice
It has until February 23, 2027, to meet the listing rule; otherwise, its shares could face delisting.
Sources
8-K, filed Sep 2, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days from receipt of the Notice, or until February 23…View ↗
-
Aug 18, 2026
IRIDEX reaffirmed its full-year revenue guidance
The company kept its 2026 revenue outlook at $51 million to $53 million.
Sources
8-K, filed Aug 18, 2026
The Company is reaffirming its annual revenue guidance for the full year 2026 of between $51 million and $53 million. Updating on cash…View ↗
Flat. Revenue was $52.7M in FY2026, about the same as the $57M of FY2023.
Who Do They Compete With?
Competes with Alcon, Carl Zeiss Meditec, Lumenis, Nidek, Lumibird, ARC, Meridian, OD-OS, Norlase, Novartis, Allergan, Glaukos, Sight Sciences, New World Medical, Astellas Pharma, Pfizer, Regeneron Pharmaceuticals, and Roche Holding
10-K for FY2026, filed Apr 2, 2026Our principal ophthalmic laser competitors are Alcon Inc., Bausch Health Companies Inc., Carl Zeiss Meditec AG, Lumenis Ltd., Nidek Co.…View ↗
Loading...
